
News|Articles|November 15, 2021
SterRx Recalls 240 Lots of 12 Products
Equipment and process issues could lead to a lack of sterility.
Advertisement
SterRx is recalling about 240 lots of 12 different products. The recall is being made because of due equipment and process issues that could lead to a lack of sterility. To date, SterRx has not received reports of adverse events associated.
These lots were distributed between December 2020 and October 2021.
The products impacted include:
- 1mg/mL Midazolam in 0.9% Sodium Chloride
- Fentanyl in 0.9% Sodium Chloride
- 1mg/mL Morphine Sulfate in 0.9% Sodium Chloride
- 1mg/mL Morphine Sulfate in 5% Dextrose
- 125mg Diltiazem HCL in 0.7% Sodium Chloride
- 125mg Diltiazem HCL in 5% Dextrose
- Norepinephrine in 0.9% Sodium Chloride
- Norepinephrine in 5% Dextrose
- Epinephrine in 0.9% Sodium Chloride
- Phenylephrine in 0.9% Sodium Chloride
- 150mEq Sodium Bicarbonate in 5% Dextrose
- 200mg Succinylcholine Chloride in 0.9% Sodium Chloride
Those with questions should call (518) 324-7983 or email
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Arpit Patel. Pharm.D., MedImpact
2
Investigational non-opioid LTG-001 reduced acute pain in phase 2b trial
3
CMS sets the 2027 Part D bid amount at $296.05, will end premium subsidy program
4
Ashley Holzworth-Nash, Pharm.D., Evernorth
5






















